Current stock page

Catalysts

ABUS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABUSArbutus Biopharma Corp

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$4.09+$0.06 (+1.49%)

Latest quote

  • Momentum
    51
  • Value
    92
  • Quality
    82
  • Risk resilience
    62
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 4, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 70/100

Momentum 51/100 and sentiment — before the next covered event.

Recent coverage
3 articles

Updated Nov 15, 2026 · Sentiment 50.00%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 51/100AIQ Edge 9/10 Strong Relative Position
Beat rate
75%
6 of 8 reported periods
Average surprise
+570.1%
Across covered historical reports
Latest result
+1393.1%
Nov 10, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 10, 2026—-$0.02$0.30+1393.1%$1M$299K
Aug 12, 2026—-$0.02-$0.03-50.0%$700K$1.01M
May 13, 2026—-$0.03$0.87+3000.0%$750K$179.13M
Mar 23, 2026—-$0.04-$0.01+71.5%$614.5K$1.05M
Nov 13, 2025—-$0.06-$0.04+28.6%$841K$529K
Aug 6, 2025—-$0.02$0.01+150.0%$1.59M$10.74M
May 14, 2025—-$0.09-$0.13-44.4%$2.24M$1.76M
Mar 27, 2025—-$0.08-$0.07+12.5%$2.26M$1.57M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
1
Buy
12-month analyst target
—
— versus current price
Based on 1 analyst observations. Targets are estimates, not predictions.
No analyst target path in this snapshot.
Low target
—
—
Average target
—
—
High target
—
—

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 4, 2027

Next known earnings or reporting date.

EPS estimate-$0.02

Current analyst expectation for the upcoming report.

Revenue estimate$1M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score51

Where event reaction would show up first.

AIQ score70/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
1

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
0
Negative
0
gurufocus.com · Sep 30, 2026

Arbutus Biopharma (ABUS) Shares Rise on $230M Share Buyback Completion

On September 30, 2026, Arbutus Biopharma Corp (NASDAQ: ABUS) saw its stock gain momentum following the completion of a tender offer to repurchase up to 46 milli

rttnews.com · Aug 21, 2026

Arbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback

Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders.

manilatimes.net · Aug 21, 2026

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction” Tender Offer

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ('Arbutus” or the 'Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified 'Dutch Auction” tender offer (the 'Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company’s cash on hand.

Open full news and sentiment

ABUS Catalysts FAQ

What are the next catalysts for ABUS stock?

ABUS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ABUS stock?

Upcoming events that could move ABUS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ABUS's next earnings report affect the stock?

ABUS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ABUS stock higher?

ABUS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ABUS stock?

ABUS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.